Digitalhealthcareforrespiratorydisease

TonyKeatingChiefExecutiveOfficerandManagingDirector

tony@resapphealth.com.au

ASXTheCEOSessions15March2016

ASX:RAP

DisclaimerThispresentationhasbeenpreparedbyResApp HealthLimited(“ResApp”).The informationcontained inthispresentation isaprofessionalopiniononlyandisgiveningoodfaith.Certaininformationinthisdocumenthasbeenderived fromthirdpartiesandthoughResApp hasnoreasontobelievethatitisnotaccurate, reliableorcomplete,ithasnotbeenindependently auditedorverifiedbyResApp.Any forward-lookingstatementsincluded inthisdocument involvesubjective judgmentandanalysisandaresubjecttouncertainties,risksandcontingencies, manyofwhichareoutsidethecontrolof,andmaybeunknown to,ResApp.Inparticular,theyspeakonlyasofthedateofthisdocument, theyassumethesuccessofResApp’s strategies,andtheyaresubjecttosignificantregulatory,business,competitiveandeconomicuncertaintiesand risks.Actualfutureeventsmayvarymateriallyfromtheforward-lookingstatementsandtheassumptionsonwhichtheforward-lookingstatementsarebased.Recipientsofthisdocument (Recipients)arecautioned tonotplaceundue relianceonsuchforward-lookingstatements.ResApp makesno representationorwarrantyastotheaccuracy, reliabilityorcompletenessofinformationinthisdocumentanddoesnottakeresponsibility for updatinganyinformationorcorrectinganyerrororomissionwhichmaybecomeapparentafterthisdocumenthasbeenissued.

Totheextentpermittedbylaw,ResApp anditsofficers,employees,relatedbodiescorporateandagents(Agents)disclaimallliability,direct,indirectorconsequential (andwhetherornotarisingoutofthenegligence,defaultorlackofcareofResApp and/oranyofitsAgents)foranylossordamagesufferedbyaRecipientorotherpersonsarisingoutof,orinconnectionwith,anyuseorrelianceon thispresentationorinformation.

Thispresentation isnotanoffer,invitation,solicitationor recommendationwithrespecttothesubscription for,purchaseorsaleofanysecurity,andneither thispresentationnoranythinginitshallformthebasisforanycontractorcommitmentwhatsoever.

AllamountsinAustraliandollarsunlessstatedotherwise.

2

Digitalhealthcareforrespiratorydisease

§ Developing theworld’s firstclinically-tested, regulatory-approved respiratory diseasediagnostic testforsmartphones - Noadditionalhardware needed- Uniqueopportunity tointegrateintotelehealth providers’existingplatforms- Appstoprovideclinical-quality(‘GoldStandard’)diagnostictestsandchronicdiseasemanagement

toolsdirectlytoconsumersandhealthcareproviders§ Hugeglobalmarket,700M+ doctorvisitsannually for respiratory disease1

§ Strong clinicalevidence frommultiple pediatric clinicalstudies, adultstudyunderway§ Successful Pre-Submission meeting heldwith theUSFDA inQ12016§ Fully-funded tobringproduct toUSmarket inlate2016

3

1.ResAppestimate basedonOECDdoctorvisitspercapitadataandassuming10%ofvisitsare forrespiratorydisease (basedonUSdata)

Companyoverview

4

CapitalStructure(ASX:RAP)MarketCap. $151M

SharePriceas of14March 2016

$0.26

Shares onIssue1 580M

Performance Shares2 93.75M

Options3 15.47M

StaffIncentiveOptions4 25M

CashBalanceas of31December 2015

$2.7M

1. Includes 121Mescrowed shares2. Issuedonachieving $20Mofannual revenue oronanacquisition3. Exercise price of2.6c,expire 31December 20164. IssuedtoMD, 5Moptions atexercise price of2.5c,5Mat5cand10M

at10c,5yearexpiry;Issued toDr Abeyratne, 3Mat5cand2Mat10c

BoardofDirectorsDrRogerAston Non-Executive Chairman(Chairman ofOncosil,formerCEOofMayne Pharma,CambridgeAntibody,cofounder ofpSivida Corp)Dr TonyKeating Managing DirectorandCEO(formerDirector,CommercialEngagement ofUniQuest,engineeringmanagementroleswithExa Corporation)Mr BrianLeedman ExecutiveDirectorandVP(ChairofAusBiotech-WA,co-founderofImugene LtdandOncosil MedicalLtd,formerVP,IRatpSivida Corp. andGroupMarketingManageratE&Y-WA)Mr AdamSierakowski Non-ExecutiveDirectorMr ChrisNtoumenopoulos Non-ExecutiveDirector

Substantial ShareholdersFreemanRoad:7.59%UniQuestPtyLtd:7.28%Mr BrianLeedman:5.28%Top20Shareholders:43.7%

Diagnosisofrespiratorydiseaseisthemostcommonoutcomefromavisittothedoctor

5

AcuteconditionsURTIs,influenza,bronchitis,bronchiolitis,pneumonia,pertussis,croupChronicConditionsAsthma,COPD,cysticfibrosis,bronchiectasis

§ 125M doctorvisits1 intheUSforrespiratorydisease(10%ofallvisits)

§ 6-8M doctorvisits2 inAustraliaforrespiratorydisease

§ Est.700M+ doctorvisitsglobally3 forrespiratorydisease

§ HighprevalenceandgrowthinAsia

1.Ambulatorycasevisits,NationalAmbulatoryMedical CareSurvey20102.AustralianLungFoundation3.BasedonOECDdoctorvisitspercapitadataandassuming10%ofvisitsare forrespiratorydisease (basedonUSdata)

Currentlydiagnosedusingstethoscope,imaging(x-ray,CT),bloodand/orsputumtests

Revolutionarytoolbasedonsoundsignatures

§ Exclusiveworldwidelicensetomachinelearningtechnologydeveloped byA/Prof.AbeyratneatTheUniversityofQueensland

§ Usessignaturesincoughingandbreathingsounds todiagnosedisease

§ PatentapplicationfiledinUS,Australia,Europe,China,JapanandSouth Korea

§ Canbedeliveredusingtoday’ssmartphones, noadditionalhardwarerequired

6

Cough Spectra too is different

Ann

als

of B

ME

, US

A, 2

013

Cough Spectra too is different

Ann

als

of B

ME

, US

A, 2

013

Easytouse,instantdiagnosisonasmartphone

7

Strongclinicalevidence

8

2013Study Sensitivity Specificity Accuracy

Pneumoniavs.allrespiratory 94% 100% 96%

Asthmavs.pneumonia 100% 80% 90%

1. Abeyratne etal.,AnnalsofBiomedicalEngineering, 20132. Kosashi etal., IEEE Transactions inBiomedicalEngineering, 2015

Currentstudy(startedMarch2015)- FundedbyResApp- ManagedbyTheUniversityofQueensland- Sites:Joondalup HealthCampusandPrincess

MargaretHospital,Perth,Australia- 598pediatric patientsenrolled todate

(continuing)

Proofofconceptstudy(2013)- FundedbyTheBillandMelindaGates

FoundationandTheUniversityofQueensland- Site:Sardjito Hospital,Indonesia- 91patients,majorityundertheageof5- Resultspublishedinpeer-reviewed journals1,2

2015StudyPreliminaryResults Sensitivity Specificity Accuracy

Pneumoniavs.norespiratory 100% 95% 97%

Asthmavs.norespiratory 97% 92% 95%

Bronchiolitis vs.norespiratory 100% 100% 100%

Croupvs.norespiratory 94% 100% 99%

URTIvs.norespiratory 100% 95% 96%

Pneumonia,crouporbronchiolitisvs.URTI 89-100% 90-95% 89-98%

Differentialdiagnosisofpneumonia,croup,URTIandbronchiolitis

92-100% 85-97% 91-99%

Telehealthisoneofthebiggesttrendsinhealthcare

9

§ TwolargestUSpharmacychainshaverecentlyannouncedpartnershipswithtelehealth providers

§ Teladoc andAmericanWell: 10M+customerseach§ InsurerssuchasCigna,Aetna,UnitedHealthcare§ EmployerssuchasBankofAmerica,Volvo,Yahoo!§ Hospital systemssuchasMountSinai

75MUStelehealth consults

(‘evisits’) in2014(Deloitte)

56%annual growthrate

(IHS)

$12-$16BTotalUSmarketopportunity

(GoldmanSachs,Deloitte,Teladoc)

$50BTotalglobalmarket

opportunity(Deloitte)

ResAppdirectlyaddressesthemostcommondiseaseencounteredbytelehealthproviders

10

1.Uscher-PinesandMehrotra (HealthAffairs,2014)2.IHS3.BasedonOECDdoctorvisitspercapitadataandassuming10%ofvisitsare forrespiratorydisease (basedonUSdata)

§ 30%of telehealthconsults foracuterespiratory disease1

§ 22.5Mtelehealth consults peryeartoday foracuterespiratory disease§ Number oftelehealth consultations growing at56%peryear2

§ 700M+ globaldoctor visitseachyearforrespiratory disease3- Accessthroughgrowthintelehealthplus in-persontests(in-clinic,in-hospital)

ThemarketsegmentaddressedbyResAppisenormous

Marketsegmentsandbusinessmodel

11

Telehealth Clinical use Developingworld Directtoconsumer

Commercialstrategy

Partnerwithtelehealthproviderstoreach10sofmillionsofpatients

Initialuseinemergencydepartments(ED),extendingtoregularclinics

Partnerwithleadinginternationalaidagencies toequipfieldpersonnel

Directtoconsumerviaappstorestotargetgrowthinconsumer-ledhealth

Valueproposition

✓ Theonlyremoteclinically-accuratediagnostictool available

✓ Easilyintegratedintoexistingplatforms

✓ Reducecosts(<$10vs >$200forx-ray)

✓ Reducetime(x-rayadds~30mins)

✓ Lowcost,accurate&fast✓ Usablebynon-medical

personnel✓ IntegratesintoIMCI

framework

✓ Convenience✓ Low cost✓ Consumer

empowerment

Revenuemodel B2Bpertestfee(<$10)fromtelehealth providers

B2Bpertestfee(<$10)fromhealthcarepayors

B2Blowcostannualsubscriptionfromaidagencies

B2C downloadandpertestfeedirectfromconsumers

Marketsize • 22.5Mrespiratory-relatedUStelehealth consultsp.a.• 56%growthrate• Majortelehealth providershave10sofmillionsofcustomerseach

• 13.4MUSEDvisitsforrespiratorydiseasep.a.1(~4.6Mforchildren)• 700M+ambulatoryrespiratoryconsultationsp.a.2

• 1Mchilddeathsduetopneumoniap.a.3• 151Mcasesofpneumoniaindevelopingcountriesp.a.3

• 400MiPhoneusers4• 1.6BAndroidusers4• mHealth appmarketexpectedtogrowto$25Bbyendof20175

1.NHAMCS(2011)2.ResAppestimate basedonOECDpercapitadata3.WHOestimate4.Statista (2014estimates)5.Research2guidance mHealth AppDeveloperEconomics(2014)

2015:Anoutstandingyearofachievements

12

¨ Initiatedandenrolled 598patients inmulti-site pediatricclinicalstudy¨ Reported positive preliminary results frompediatric clinicalstudy¨ Initiatedadultclinicalstudy¨ Appointed best-in-classFDAregulatory consultant – Experien Group (Sunnyvale, CA)¨ FiledPre-Submission packagewith theUSFDA¨ Builtup theteamwith threenewhires(software development, clinical/regulatory

operations)¨ Developed highperformance cross-platform software library thatcanbedeployed via

smartphone app,SDKorcloud-hosted Software-as-a-Service API¨ RaisedAU$4million and listedon theASX

✓

✓

✓

✓

✓

✓

✓

✓

Milestonesfor2016

13

¨ Obtainedapproval toenrolladultpatientsatsecondhospital site,TheWesleyHospital (Q1)¨ Reported interimresults frompediatric studydemonstrating superiority tostethoscope for

lower respiratory tractdisease (Q1)¨ Securedpartnership withglobalhumanitarian organisation fordeveloping world trial(Q1)¨ Successfully heldPre-Submission meeting withtheUSFDA(Q1)¨ Reportupdated results from pediatric clinicalstudy (Q1)¨ Reportpreliminary results from adultclinicalstudy (Q2)¨ Initiatepivotal clinicalstudy inUSandAustralia (Q2)¨ Filedenovopremarket submission withFDAfor firstResApp product (mid-year)¨ FDAmarketing approval for firstResAppproduct (Q4)

✓

✓

✓

✓

Summary

§ Revolutionary technology – diagnosis andmanagement of respiratory diseasewithout theneed foradditional hardware

§ Multi-sitepediatric clinicalstudyprogressing verywellwithover500patientsenrolled andpositive preliminary results- Continuingenrolmentbeyondinitialtargetpatientnumbersduetothehighvalueofdatacollected

§ Enrolment inadultclinicalstudyprogressing quickly, approvalobtained for secondsite§ USFDAPre-SubmissionmeetingheldinQ12016

- Confirmeddenovoregulatory pathway,combinedUSandAustralianpivotalclinicalstudy

§ Further results frompediatric andadultclinical studiesdueinQ1-Q22016§ On-tracktobringproducttomarketinlate2016, launchviatelehealth partner toreach

millions ofpatientsquickly

14